Trial · NCT05568888
Results by group22
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 22
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Proportion of Participants With All-cause 6-hour Mortality | BE1116 | All-cause Mortality in ITT Analysis Set | 7.3 | Percentage of participants | |
| Proportion of Participants With All-cause 6-hour Mortality | Placebo | All-cause Mortality in ITT Analysis Set | 4.6 | Percentage of participants | |
| Proportion of Participants With All-cause 6-hour Mortality | BE1116 | All-cause Mortality in mITT Analysis Set | 7.2 | Percentage of participants | |
| Proportion of Participants With All-cause 6-hour Mortality | Placebo | All-cause Mortality in mITT Analysis Set | 4.1 | Percentage of participants | |
| Proportion of Participants With All-cause 24-hour In-hospital Mortality | BE1116 | 11.1 | Percentage of participants | ||
| Proportion of Participants With All-cause 24-hour In-hospital Mortality | Placebo | 7.3 | Percentage of participants | ||
| Proportion of Participants With All-cause In-hospital Mortality Up to 30 Days After Randomization | BE1116 | 24.8 | Percentage of participants | ||
| Proportion of Participants With All-cause In-hospital Mortality Up to 30 Days After Randomization | Placebo | 18.6 | Percentage of participants | ||
| Proportion of Participants Who Underwent Surgical or Interventional Radiological Procedures to Stop Bleeding Related to the Primary Injury | BE1116 | 78.0 | Percentage of participants | ||
| Proportion of Participants Who Underwent Surgical or Interventional Radiological Procedures to Stop Bleeding Related to the Primary Injury | Placebo | 75.5 | Percentage of participants | ||
| Number of Participants With Treatment-Emergent Serious Adverse Events (SAEs) | BE1116 | 34 | Count of participants | ||
| Number of Participants With Treatment-Emergent Serious Adverse Events (SAEs) | Placebo | 46 | Count of participants | ||
| Number of Participants With In-hospital Overall and Related Thromboembolic Events (TEEs) | BE1116 | Overall TEEs | 133 | Count of participants | |
| Number of Participants With In-hospital Overall and Related Thromboembolic Events (TEEs) | Placebo | Overall TEEs | 139 | Count of participants | |
| Number of Participants With In-hospital Overall and Related Thromboembolic Events (TEEs) | BE1116 | Related TEEs | 46 | Count of participants | |
| Number of Participants With In-hospital Overall and Related Thromboembolic Events (TEEs) | Placebo | Related TEEs | 51 | Count of participants | |
| Number of Participants With Acute Respiratory Distress Syndrome (ARDS) | BE1116 | 31 | Count of participants | ||
| Number of Participants With Acute Respiratory Distress Syndrome (ARDS) | Placebo | 28 | Count of participants | ||
| Number of Participants With Multiple Organ Failure | BE1116 | 59 | Count of participants | ||
| Number of Participants With Multiple Organ Failure | Placebo | 53 | Count of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05568888/results